Antimicrobial and Amyloidogenic Activity of Peptides. Can Antimicrobial Peptides Be Used against SARS-CoV-2?

• Published in: International journal of molecular sciences Vol. 21; no. 24; p. 9552
• Main Authors: Kurpe, Stanislav R., Grishin, Sergei Yu, Surin, Alexey K., Panfilov, Alexander V., Slizen, Mikhail V., Chowdhury, Saikat D., Galzitskaya, Oxana V.
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 15.12.2020; MDPI
• Subjects: Amyloidogenic Proteins - adverse effects; Amyloidogenic Proteins - pharmacology; Amyloidogenic Proteins - therapeutic use; Animals; Antibiotics; Antimicrobial agents; Bacteria; Coronavirus Infections - drug therapy; Coronaviruses; COVID-19 - drug therapy; COVID-19 - virology; Drug resistance; Fungi; Humans; Infections; Medicine; Metabolism; Pathogens; Peptides; Pore Forming Cytotoxic Proteins - adverse effects; Pore Forming Cytotoxic Proteins - pharmacology; Pore Forming Cytotoxic Proteins - therapeutic use; Proteins; Proteome; Research methodology; Review; SARS-CoV-2 - drug effects; Severe acute respiratory syndrome coronavirus 2; Viral infections; toxicity; amyloidogenic regions; antibacterial peptides; coronavirus disease 2019 (COVID-19); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); mass spectrometry; proteome
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms21249552

At present, much attention is paid to the use of antimicrobial peptides (AMPs) of natural and artificial origin to combat pathogens. AMPs have several points that determine their biological activity. We analyzed the structural properties of AMPs, as well as described their mechanism of action and impact on pathogenic bacteria and viruses. Recently published data on the development of new AMP drugs based on a combination of molecular design and genetic engineering approaches are presented. In this article, we have focused on information on the amyloidogenic properties of AMP. This review examines AMP development strategies from the perspective of the current high prevalence of antibiotic-resistant bacteria, and the potential prospects and challenges of using AMPs against infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).